Voyager Therapeutics, Inc. $VYGR Shares Sold by Armistice Capital LLC

Armistice Capital LLC lessened its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 4.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 4,000,000 shares of the company’s stock after selling 200,000 shares during the quarter. Armistice Capital LLC owned approximately 0.07% of Voyager Therapeutics worth $15,720,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Altshuler Shaham Ltd acquired a new stake in Voyager Therapeutics during the 4th quarter worth $801,000. Deutsche Bank AG purchased a new position in Voyager Therapeutics during the 4th quarter worth $124,000. Virtu Financial LLC acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth $93,000. Jane Street Group LLC grew its stake in shares of Voyager Therapeutics by 92.6% during the 2nd quarter. Jane Street Group LLC now owns 27,844 shares of the company’s stock worth $87,000 after purchasing an additional 13,389 shares during the period. Finally, Occudo Quantitative Strategies LP acquired a new position in shares of Voyager Therapeutics during the 2nd quarter worth $78,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Wednesday, April 15th. HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a report on Tuesday, May 26th. Truist Financial raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Wall Street Zen cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Price Performance

VYGR opened at $3.62 on Thursday. The stock has a market capitalization of $218.72 million, a PE ratio of -1.84 and a beta of 1.25. The firm’s fifty day moving average price is $3.81 and its 200 day moving average price is $3.93. Voyager Therapeutics, Inc. has a 12-month low of $2.83 and a 12-month high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The firm had revenue of $1.19 million for the quarter, compared to analysts’ expectations of $8.79 million. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. On average, equities research analysts forecast that Voyager Therapeutics, Inc. will post -1.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 11,511 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total transaction of $44,547.57. Following the completion of the sale, the chief executive officer owned 472,549 shares in the company, valued at $1,828,764.63. The trade was a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 12.70% of the stock is currently owned by insiders.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.